Locations:
Search IconSearch
August 12, 2021/Cancer

Treating a Rare Ewing Sarcoma Case With Patience and Persistence

Slight deviation from treatment paradigm salvages significant anatomy

21-CHP-2168758-Hero-Opt2

A 4-year-old patient presented with a 7.2 cm tumor located in her buttock and was later diagnosed with Ewing sarcoma. The tumor was arising in the coccyx with extension into the gluteal musculature, the pelvic floor muscles and pushing up tightly against the rectum. Her physicians at Cleveland Clinic Children’s say that approaching her treatment with “patience and persistence” helped salvage significant anatomy, potentially preventing lifetime use of a colostomy bag.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Ewing sarcoma can occur any place in the body, although it’s frequently reported in musculoskeletal sites in the extremities and pelvis. The sarcoma-causing mutation is initiated by the fusion of the Ewing gene (EWS) with a partner gene. FLI1 is the most common variant, although there are several other fusion partners. In this case, the patient had the FEV gene rearrangement, an unusual partnering, making the case particularly unique.

Principles of therapy for Ewing sarcoma

Peter Anderson, MD, the patient’s pediatric oncologist, explains that the principles of therapy for Ewing sarcoma, like other sarcomas, is to first shrink the tumor with effective therapy; this is, historically, a 10-week regimen.

“This step is followed by local control, which is almost always either surgery, radiation or both, although the choice of when to do surgery, radiation or both depends on site, size of the tumor and experience of the team,” he says. More chemotherapy often follows this to help prevent recurrence and metastasis of the tumor.

In this case, however, the tumor responded remarkably well to the chemotherapy. The team decided to keep treating it to hopefully make surgery less damaging. The original concern was that the rectum would have to be removed to gain a safe margin on the tumor. However, the tumor continued to shrink with every round of treatment. They used all 14 cycles of treatment before proceeding with the surgery.

Lukas Nystrom, MD, the patient’s orthopaedic oncologist, says this approach reduced the tumor, allowing for a more minimal resection. “We were ultimately able to salvage the rectum, removing only a small part of her tailbone and gluteal muscles.”

Advertisement

The team was elated when postoperative pathology reports showed 100% necrosis of cancer cells, eliminating the need for radiation in a sensitive area. The tumor was effectively treated and the patient’s function was spared.

Drs. Anderson and Nystrom both say that following a conventional treatment paradigm – doing the surgery in the middle of the chemotherapy – would have necessitated significant additional resection of normal anatomy and, almost certainly, would have resulted in the patient needing a colostomy.

When considering this approach, Dr. Anderson says he was confident that such a positive treatment response and the relative size of the tumor was unlikely to result in relapse while the patient was still in therapy.

On her way to becoming a ‘statistical outlier’

A single lung nodule was detected on the patient’s scan at follow-up. She was treated with novel outpatient chemotherapy that did not require hospital admission. Her radiation oncologist, Erin Murphy, MD, used stereotactic body radiotherapy to treat the nodule precisely and with no side effects and no sign of recurrence at present. Dr. Anderson reports, “The patient is having a happy, well-adjusted summer.”

She will receive scans every four months, and then less frequently after that. “We can’t promise a cure, but we think she is on her way to becoming a statistical outlier,” he says.

‘Doing what’s right for the child’

This is a case of persistence and patience, but Dr. Nystrom says Cleveland Clinic Children’s is also well-positioned to handle complex cases like this.

“Not only do we have every specialty involved in cancer care under one roof, but we have them all in one room.”

Advertisement

Cases like this come up at least twice a week during pediatric Ewing sarcoma and pediatric tumor board discussions. The team also recently launched a new National Ewing Sarcoma Tumor Board, a forum that connects experts from Cleveland Clinic and other leading cancer centers.

The strong collaboration and continuity of care among all of the patient’s care team resulted in a personalized plan of care that, ultimately, led to an optimal outcome. Both physicians agree that multidisciplinary care and focused case-related discourse allow the team to think outside the box in ways that engender innovation in care and prioritize the patient.

Dr. Anderson sums it up. “Ultimately, it’s about doing what’s right for the child.”

Advertisement

Related Articles

Silhouettes of man and woman
February 7, 2025/Cancer/News & Insight
Pharmacokinetics of Many Anticancer Drugs Differ Among Sexes

Slower drug elimination from the body among females may impact safety and efficacy

Mobile mammography van
February 6, 2025/Cancer/News & Insight
Increasing Breast Cancer Screening in Women Experiencing Homelessness

Partnerships with local social service agencies key to program success

Eye melanoma
February 4, 2025/Cancer
Novel Neoadjuvant Treatment Trial for Uveal Melanoma

Oral medication may have potential to preserve vision and shrink tumors prior to surgery or radiation

Specialty pharmacy
January 24, 2025/Cancer/News & Insight
Researchers Seek Actionable Ways to Reduce Time to Treatment of Multiple Myeloma

Study examines modifiable determinants of health disparities

Woman wearing pink scarf
January 17, 2025/Cancer/News & Insight
Exceptional Responders to Metastatic Breast Cancer Treatment Characterized

Findings may guide future research and personalized treatments

Tumor-Infiltrating Lymphocytes (TIL) therapy
January 6, 2025/Cancer/News & Insight
Tumor-Infiltrating Lymphocytes Therapy Now Available for Treating Unresectable or Metastatic Melanoma

Cleveland Clinic Cancer Institute among select group of centers to administer highly personalized treatment

Woman with breast cancer
January 2, 2025/Cancer/News & Insight
Real-World Insights of KEYNOTE-522 Regimen Adoption for Treating Triple-Negative Breast Cancer

Real-world results reporting aims to make treatments safer and more effective

DNA strand
December 31, 2024/Cancer/News & Insight
New Data Further Support Breast Cancer Polygenic Risk Score

Ongoing clinical validation in diverse populations refine breast cancer risk substratification

Ad